Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E145.66 EPS (ttm)0.19 Insider Own1.00% Shs Outstand293.55M Perf Week7.33%
Market Cap8.08B Forward P/E43.02 EPS next Y0.64 Insider Trans-33.76% Shs Float276.46M Perf Month-1.40%
Income58.20M PEG3.17 EPS next Q0.08 Inst Own81.00% Short Float7.23% Perf Quarter2.00%
Sales319.70M P/S25.28 EPS this Y63.70% Inst Trans0.10% Short Ratio5.17 Perf Half Y29.13%
Book/sh0.51 P/B53.98 EPS next Y137.04% ROA10.40% Target Price29.71 Perf Year135.90%
Cash/sh1.19 P/C23.14 EPS next 5Y46.00% ROE59.70% 52W Range10.04 - 32.50 Perf YTD84.64%
Dividend- P/FCF55.09 EPS past 5Y-19.90% ROI-15.10% 52W High-15.29% Beta1.90
Dividend %- Quick Ratio4.10 Sales past 5Y-7.90% Gross Margin96.70% 52W Low174.20% ATR1.37
Employees287 Current Ratio4.10 Sales Q/Q172.70% Oper. Margin22.90% RSI (14)57.84 Volatility6.18% 4.35%
OptionableYes Debt/Eq0.00 EPS Q/Q137.30% Profit Margin18.20% Rel Volume1.31 Prev Close28.30
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout0.00% Avg Volume3.86M Price27.53
Recom2.30 SMA208.10% SMA503.89% SMA20020.22% Volume5,057,234 Change-2.72%
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Oct-18-17 04:05PM  Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017 Business Wire
07:50AM  Featured Company News - Exelixis' Cabozantinib Met Primary Endpoint in Phase-3 CELESTIAL Trial for Advanced Hepatocellular Carcinoma ACCESSWIRE
07:32AM  Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug Zacks
Oct-17-17 10:03AM  Company News For Oct 17, 2017 Zacks
09:15AM  FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx Zacks
08:33AM  Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session Zacks
08:18AM  Why Exelixis' Rebound Is Just Getting Started Motley Fool
08:10AM  Today's Research Reports on Stocks to Watch: Dynavax and Exelixis ACCESSWIRE
08:05AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : October 17, 2017 Capital Cube
Oct-16-17 05:04PM  What Happened in the Stock Market Today Motley Fool +17.21%
04:40PM  Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News Investor's Business Daily
04:32PM  Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dip Associated Press
03:49PM  Wall Street High on Monday GuruFocus.com
12:57PM  Why Exelixis, Inc. Rose Higher Today Motley Fool
09:22AM  Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers TheStreet.com
09:22AM  Exelixis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers TheStreet.com
09:10AM  Exelixis Cancer Treatment Hits Key Milestone 24/7 Wall St.
07:26AM  Exelixis shares surge 19% premarket after FDA grants priority review to kidney cancer drug MarketWatch
07:15AM  Exelixis cancer drug meets key goal in late-stage trial Reuters
07:02AM  Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma Business Wire
06:59AM  Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma Business Wire
06:58AM  Exelixis Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma Business Wire
Oct-12-17 02:35PM  Top 5 Biotech Stocks for 2017 Investopedia
Oct-09-17 11:30AM  ETFs with exposure to Exelixis, Inc. : October 9, 2017 Capital Cube
08:04AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Oct-06-17 09:11AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
08:15AM  New Research: Key Drivers of Growth for Bed Bath and Beyond, The Finish Line, Exelixis, Garmin, Juno Therapeutics, and Mattel - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-05-17 10:37AM  The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September Motley Fool
07:42AM  Could Cabometyx Be Exelixiss Long-Term Growth Driver? Market Realist
Oct-04-17 05:35PM  How Is Cabometyx and Cometriq Positioned after 1H17? Market Realist
04:43PM  Why These Biotechs Are Leading The Group Near A 21-Month High Investor's Business Daily
04:06PM  How Did Exelixis Perform in 1H17? Market Realist
02:11PM  Analyst Recommendations for Exelixis in October 2017 Market Realist
08:00AM  Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORt Inverse Agonist Program Business Wire
Oct-02-17 02:00PM  3 Beaten-Down Biotech Stocks to Buy Right Now Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-30-17 10:47AM  Better Buy: Exelixis, Inc. vs. Immunogen, Inc. Motley Fool
Sep-26-17 08:18AM  3 Reasons to Buy the Dip With Exelixis Motley Fool
Sep-25-17 08:20AM  Today's Research Reports on Stocks to Watch: Exelixis and Versartis ACCESSWIRE
08:19AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : September 25, 2017 Capital Cube
Sep-24-17 09:00PM  Exelixis Provides Update on Collaborator Daiichi Sankyos Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study Business Wire
09:09AM  3 Monster Biotech Stocks in the Making Motley Fool
Sep-22-17 03:01PM  Why Exelixis, Inc. Slumped Today Motley Fool -12.64%
06:08AM  These 3 Stocks Are Priced for Perfection. Can They Deliver? Motley Fool
Sep-20-17 06:32AM  Why Exelixis Wouldn't Be a Warren Buffett Stock Motley Fool
05:37AM  [$$] Exelixis CEO, CFO Sell $11 Million in Stock Barrons.com
Sep-19-17 04:05PM  Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25 Business Wire
Sep-15-17 01:18PM  Why Amgen, Lilly, J&J Are Interested In These Small Biotechs Investor's Business Daily
06:04AM  Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis? Motley Fool
Sep-14-17 08:21PM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : September 15, 2017 Capital Cube
03:19PM  Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale Motley Fool
Sep-13-17 09:44AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : September 13, 2017 Capital Cube
Sep-11-17 10:10AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-10-17 07:17AM  Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors Motley Fool
Sep-09-17 06:09PM  Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 Business Wire
Sep-08-17 03:22PM  Exelixis Recovers From Bristol-Inspired Pitfall In Kidney Cancer Investor's Business Daily
10:34AM  2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August Motley Fool
10:23AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
06:08AM  Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock Motley Fool
Sep-07-17 08:16AM  Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy Business Wire -8.91%
Sep-06-17 05:23PM  Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress Business Wire
Sep-02-17 08:09AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-01-17 08:47AM  Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions? Zacks
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-31-17 08:00AM  Today's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation ACCESSWIRE
Aug-29-17 04:05PM  Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13 Business Wire
01:59PM  Analyst Recommendations for Regeneron Pharmaceuticals in August Market Realist
Aug-27-17 03:04PM  Can Buying Exelixis Stock Still Make You Rich? Motley Fool
Aug-24-17 10:35AM  4 of the Highest-Growth Stocks in Biotech Today Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-18-17 07:40AM  Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer ACCESSWIRE
Aug-17-17 05:59PM  Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx Zacks
12:31PM  Edited Transcript of EXEL earnings conference call or presentation 2-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-16-17 09:45AM  Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc. ACCESSWIRE
07:00AM  Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer Business Wire
Aug-15-17 04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
Aug-14-17 01:06PM  What Amgens Analysts Recommend in August 2017 Market Realist
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-11-17 08:02AM  IHS Markit Score upgrades Exelixis Inc to 72 out of 100, despite ranking positively in only one IHS Markit category. Markit
Aug-09-17 11:18AM  Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts Motley Fool
Aug-04-17 04:35PM  Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass Zacks
02:50PM  Exelixis, Inc. Grows Revenue, Eyes Treating More Patients Motley Fool
10:12AM  Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag Zacks
Aug-03-17 04:41PM  Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates Zacks
04:21PM  Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales Zacks
03:41PM  3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance Motley Fool
02:41PM  The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom Benzinga
11:33AM  Dynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch SmarterAnalyst
01:07AM  Exelixis tops Street 2Q forecasts Associated Press
Aug-02-17 04:05PM  Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update Business Wire
12:20PM  Investor Network: Exelixis, Inc. to Host Earnings Call ACCESSWIRE
10:24AM  Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Aug-01-17 10:46AM  Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2 Zacks
08:00AM  Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress Business Wire
Jul-31-17 01:56PM  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up Zacks
10:44AM  Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise Zacks
Jul-28-17 02:33PM  Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line Zacks
Jul-27-17 12:04PM  Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View Zacks
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Option Exercise9.9133,334330,340216,339Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 28Option Exercise1.9025,00047,500292,946Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 28Sale24.3225,000608,000267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Sale23.7433,334791,349183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Option Exercise1.902,3024,374270,248Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Sale23.9433,333797,992183,005Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Sale23.902,30255,018267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Sale23.6833,333789,325183,005Sep 28 07:45 PM
PAPADOPOULOS STELIOSDirectorSep 22Sale25.4010,000254,0000Sep 22 07:07 PM
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM